Rare Disease Day is held on the last day of February to raise awareness for rare diseases and address drug development ...

BioNTech and partner DualityBio are accelerating the development of their B7-H3 antibody-drug conjugate into a phase 3 trial for metastatic castration-resistant prostate cancer (mCRPC). | BioNTech and ...

Overview Artificial intelligence seems to be transforming drug discovery in 2026, enabling faster molecule design, smarter clinical trials, and reduced R&D ...

Generate:Biomedicines is the latest biotech to benefit from a renewed appetite from investors for publicly listed drug developers. | Generate:Biomedicines is the latest biotech to benefit from a ...

BioTechnique expands 3PL services with compliant storage, inventory control, and GDP‑aligned shipping for regulated ...

New identity reflects Company's evolution into an innovative data driven biotech company leveraging MITOLINE and mitochondrial carrier biology across oncology and inflammatory metabolic diseases Neve ...

Continuing with the rare disease theme (Rare Disease Day is Feb 28), Elisabeth Gardiner of Tevard Biosciences explains in a video interview that research into ultra-rare conditions continues to yield ...

Chinese assets have outgrown a “bargain basement” label as the upfront value of licensing deals involving them has increased, ...

Today, Gubra releases its Annual Report for 2025 showing the strongest financial results in Gubra's history. Group revenue and operating profit amounted to DKK 2.6 billion and DKK 2.2 billion, ...

A blockbuster drug is a best-selling medication earning over $1 billion annually. Learn about them and how they revolutionize ...

How innovative technologies like AI and gene editing are advancing rare disease drug discovery and development.